AstraZeneca PLC (AZN)
| Previous close | 78.27 |
| Open | 79.29 |
| Bid | 79.20 x 100 |
| Ask | 79.34 x 200 |
| Day's range | 79.08 - 79.50 |
| 52-week range | 60.47 - 87.68 |
| Volume | |
| Avg. volume | 4,433,122 |
| Market cap | 246.752B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 38.49 |
| EPS (TTM) | 2.06 |
| Earnings date | 12 Nov 2024 |
| Forward dividend & yield | 1.49 (1.90%) |
| Ex-dividend date | 09 Aug 2024 |
| 1y target est | 90.89 |
Business WireIMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
WILMINGTON, Del., September 16, 2024--Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at five years for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment.
Business WireIMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
WILMINGTON, Del., September 15, 2024--Positive results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with IMFINZI in combination with neoa
Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
WILMINGTON, Del., September 13, 2024--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial clinical activity in a large cohort of patients with HER2-positive metastatic breast cancer who have brain metastases and received no more than two prior lines of therapy in the metastatic setting. Results will be presented today as a late-breaking presentation (abstract #LBA18) at the European Society
